Strength Training Response of Muscle in GLP-1 Users
Recruiting · NCT07104539 · Interventional (participants receive a specific treatment) · Lead sponsor: Virginia Polytechnic Institute and State University
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
GLP-1 medication is being prescribed for weight loss. However, GLP-1 medication may adversely affect muscle mass and muscle function. Moreover, any loss of muscle mass or muscle function with GLP-1 treatment may impair balance and increase fall risk. This is a particular concern among older adults already susceptible to the common muscle strength and muscle function loss with age, yet there is little evidence among this population. This study will address a gap in knowledge regarding the effects of GLP-1 treatment on muscle mass, muscle function, and balance/fall risk among adults age 50 and older.
Who can take part
Inclusion criteria
- Age, 50y+
- Be taking GLP-1 medicine (Weygovy or Zepbound) for 1 month or less
- Weight \<300 lb
- Pass a health and exercise readiness screening
Exclusion criteria
- Age \<50
- Weight \>300 lb
- Osteoporosis
- Active metabolic, neoplastic, or cardiovascular disease
- Unable or unwilling to provide consent
Where it is running
1 location listed across 1 US state.
- Virginia Tech - Blacksburg, Virginia, United States